Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JACOBIO PHARMACEUTICALS GROUP CO., LTD.
加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT
SHARE REPURCHASE AND CASH RESERVE UPDATE

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the "**Company**" or "**Jacobio**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that pursuant to the powers under the general mandate (the "**Share Repurchase Mandate**") given to the Board pursuant to the resolutions of the Shareholders passed at the annual general meeting of the Company (the "**AGM**"), the Company has continuously implemented share repurchases. As of May 18, 2026, the Company holds an aggregate of 7,47,800 repurchased shares as treasury shares, with a total repurchase consideration of approximately HK$34.17 million. The Company's steady pace and sustained execution of share repurchases fully demonstrate the Board's firm confidence in the Company's long-term intrinsic value and future development prospects. The Board believes that the current share price of the Company does not fully reflect its core pipeline value, commercialization potential, and ample cash reserves, and will continue to closely monitor market conditions and reserve the right to further exercise the Repurchase Mandate at appropriate times.

Meanwhile, the Group has recently and successively received the US$100 million upfront payment under the strategic collaboration with AstraZeneca and the RMB8.55 million sales royalty payment from Allist for the period from June to December 2025. As of the date of this announcement, the Group has approximately RMB2.1 billion in cash and bank balances, investments in capital protected structure deposits and available bank credit facilities, representing a strong liquidity position. Based on the current cash reserves and controlled expenditure planning, the Group's cash runway can reach at least 4 years, which is sufficient to support the continued development of core innovative oncology drug pipelines and global business expansion, further ensuring the Group's stable business development and execution of its long-term strategy. The Board firmly believes that the Company's continuous share repurchases, ample cash reserves, long-term cash flow security, and major collaboration achievements fully reflect the Group's solid fundamentals, prominent core pipeline value, and significant commercialization potential. The Company will remain focused on the development and advancement of its innovative oncology therapy pipelines, and is committed to maximizing shareholder value.

Shareholders and potential investors should note that repurchases of Shares under the Share Repurchase Mandate will be subject to market conditions and at the absolute discretion of the Board. There is no assurance of the timing, quantity or price of any repurchases or whether or not the Company will make any repurchases. Accordingly, Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, May 19, 2026

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr; Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.